## Cristoforo Comi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5680219/publications.pdf

Version: 2024-02-01

101543 114465 5,040 149 36 63 citations h-index g-index papers 161 161 161 8335 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naÃ⁻ve and drug-treated patients. Journal of Neuroinflammation, 2018, 15, 205.	7.2	174
2	<i>D</i> <scp><i>NAJC</i></scp> <i>6</i> <scp>M</scp> utations <scp>A</scp> ssociated <scp>W</scp> ith <scp>E</scp> arkinson's <scp>D</scp> isease. Annals of Neurology, 2016, 79, 244-256.	5.3	148
3	Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neuroscience Letters, 2011, 504, 9-12.	2.1	147
4	Intensive Rehabilitation Treatment in Early Parkinson's Disease. Neurorehabilitation and Neural Repair, 2015, 29, 123-131.	2.9	137
5	Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. Journal of Immunology Research, 2016, 2016, 1-15.	2.2	120
6	Intensive Rehabilitation Increases BDNF Serum Levels in Parkinsonian Patients. Neurorehabilitation and Neural Repair, 2014, 28, 163-168.	2.9	118
7	Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine, 2014, 32, 5681-5689.	3.8	116
8	A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2010, 17, 289-294.	3.3	115
9	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
10	Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 306-308.	1.9	106
11	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	10.2	101
12	Defective T cell Fas function in patients with multiple sclerosis. Neurology, 2000, 55, 921-927.	1.1	100
13	Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline. Journal of Alzheimer's Disease, 2010, 19, 1143-1148.	2.6	100
14	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Scientific Reports, 2020, 10, 20731.	3.3	96
15	Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. Scientific Reports, 2016, 6, 33738.	3.3	91
16	Effectiveness of Intensive Inpatient Rehabilitation Treatment on Disease Progression in Parkinsonian Patients. Neurorehabilitation and Neural Repair, 2012, 26, 144-150.	2.9	90
17	Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease. International Journal of Molecular Sciences, 2019, 20, 204.	4.1	86
18	Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. Journal of the Neurological Sciences, 2009, 287, 291-293.	0.6	83

#	Article	IF	CITATIONS
19	Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Frontiers in Immunology, 2019, 10, 969.	4.8	83
20	Immunity and inflammation in neurodegenerative diseases. American Journal of Neurodegenerative Disease, 2013, 2, 89-107.	0.1	83
21	The Role of Osteopontin in Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2011, 25, 179-185.	2.6	81
22	Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism and Related Disorders, 2014, 20, 27-31.	2.2	73
23	Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. Journal of Neuroimmunology, 2005, 163, 172-178.	2.3	66
24	Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies. Parkinsonism and Related Disorders, 2014, 20, 1329-1334.	2.2	64
25	Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. Frontiers in Neurology, 2018, 9, 1001.	2.4	61
26	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
27	Robotic Gait Training Is not Superior to Conventional Treadmill Training in Parkinson Disease. Neurorehabilitation and Neural Repair, 2012, 26, 1027-1034.	2.9	56
28	TAM Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration. Disease Markers, 2019, 2019, 1-13.	1.3	46
29	Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers. Journal of Alzheimer's Disease, 2011, 27, 781-790.	2.6	45
30	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
31	Dopaminergic therapies modulate the Tâ€CELL proteome of patients with Parkinson's disease. IUBMB Life, 2012, 64, 846-852.	3.4	43
32	Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson's Disease. International Journal of Molecular Sciences, 2017, 18, 242.	4.1	43
33	Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 59-65.	2.6	41
34	The role of T cell apoptosis in nervous system autoimmunity. Autoimmunity Reviews, 2012, 12, 150-156.	5.8	40
35	Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells <i>In Vitro</i> and Mouse Experimental Autoimmune Encephalomyelitis <i>In Vivo</i> Journal of Immunology Research, 2016, 2016, 1-13.	2.2	40
36	Diagnosis of psychogenic paralysis: The role of motor evoked potentials. Journal of Neurology, 2001, 248, 889-897.	3.6	39

#	Article	IF	CITATIONS
37	Variations of the perforin gene in patients with multiple sclerosis. Genes and Immunity, 2008, 9, 438-444.	4.1	39
38	Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson's disease. Brain, Behavior, and Immunity, 2020, 89, 668-674.	4.1	39
39	ICOS cooperates with CD28, IL-2, and IFN- $\hat{l}^3$ and modulates activation of human na $\tilde{A}$ ve CD4+ T cells. European Journal of Immunology, 2006, 36, 2601-2612.	2.9	38
40	Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease. Scientific Reports, 2012, 2, 953.	3.3	38
41	Transorbital Sonography in Acute Optic Neuritis: A Case-Control Study. American Journal of Neuroradiology, 2014, 35, 2371-2375.	2.4	38
42	LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 129-135.	2.3	37
43	Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage. Journal of Immunology Research, 2014, 2014, 1-9.	2.2	35
44	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Scientific Reports, 2017, 7, 43718.	3.3	35
45	Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians. Brain Sciences, 2021, 11, 237.	2.3	34
46	The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression. Clinical and Developmental Immunology, 2012, 2012, 1-6.	3.3	31
47	Defining the Epsilonâ€Sarcoglycan (SGCE) Gene Phenotypic Signature in Myoclonusâ€Dystonia: A Reappraisal of Genetic Testing Criteria. Movement Disorders, 2013, 28, 787-794.	3.9	31
48	Combined use of Kappa Free Light Chain Index and Isoelectrofocusing of Cerebro-Spinal Fluid in Diagnosing Multiple Sclerosis: Performances and Costs. Clinical Laboratory, 2017, 63, 551-559.	0.5	31
49	Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 267, 86-90.	0.6	30
50	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2017, 8, 321.	4.8	30
51	Insights into the protective role of immunity in neurodegenerative disease. Neural Regeneration Research, 2017, 12, 64.	3.0	30
52	Intrathecal kappa free light chains as markers for multiple sclerosis. Scientific Reports, 2020, 10, 20329.	3.3	29
53	The Yin-Yang of osteopontin in nervous system diseases: damage versus repair. Neural Regeneration Research, 2021, 16, 1131.	3.0	29
54	The Impact of the COVID-19 Pandemic on the Cognition of People with Dementia. International Journal of Environmental Research and Public Health, 2021, 18, 4285.	2.6	29

#	Article	IF	CITATIONS
55	MDC/CCL22 intrathecal levels in patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 547-549.	3.0	28
56	Current Understanding on the Role of Standard and Immunoproteasomes in Inflammatory/Immunological Pathways of Multiple Sclerosis. Autoimmune Diseases, 2014, 2014, 1-12.	0.6	27
57	K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up. Journal of Clinical Medicine, 2019, 8, 446.	2.4	27
58	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	9.0	26
59	<scp>CD4</scp> + <scp>Tâ€cell</scp> Transcription Factors in Idiopathic <scp>REM</scp> Sleep Behavior Disorder and Parkinson's Disease. Movement Disorders, 2021, 36, 225-229.	3.9	25
60	Anti-cytokine autoantibodies in autoimmune diseases. American Journal of Clinical and Experimental Immunology, 2012, 1, 136-46.	0.2	25
61	ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. Journal of Neuroimmunology, 2007, 186, 193-198.	2.3	24
62	Defective Fasâ€mediated Tâ€cell apoptosis predicts acute onset CIDP. Journal of the Peripheral Nervous System, 2009, 14, 101-106.	3.1	24
63	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. Disease Markers, 2021, 2021, 1-7.	1.3	24
64	Kappa free light chains could predict early disease course in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 30, 81-84.	2.0	23
65	Peripheral neuropathy as marker of severe Parkinson's disease phenotype. Movement Disorders, 2017, 32, 1256-1258.	3.9	22
66	Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurological Sciences, 2018, 39, 733-739.	1.9	22
67	Beta2-Adrenoceptor Agonists in Parkinson's Disease and Other Synucleinopathies. Journal of NeuroImmune Pharmacology, 2020, 15, 74-81.	4.1	22
68	The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 213.	2.4	21
69	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. Livers, 2022, 2, 30-76.	1.9	21
70	GSK3β genetic variability in patients with Multiple Sclerosis. Neuroscience Letters, 2011, 497, 46-48.	2.1	20
71	Complex pattern of convulsive syncope in glossopharyngeal neuralgia: Video/EEG report and short review. Epilepsy and Behavior, 2011, 20, 407-409.	1.7	20
72	Variations of the UNC13D Gene in Patients with Autoimmune Lymphoproliferative Syndrome. PLoS ONE, 2013, 8, e68045.	2.5	20

#	Article	IF	Citations
73	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: From Molecular Bases to Practical Considerations. Autoimmune Diseases, 2014, 2014, 1-11.	0.6	20
74	Ultrasonography Monitoring of Optic Nerve Sheath Diameter and Retinal Vessels in Patients with Cerebral Hemorrhage. Journal of Neuroimaging, 2019, 29, 394-399.	2.0	20
75	Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis. Journal of Neurology, 2022, 269, 3249-3257.	3.6	20
76	CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. European Journal of Neurology, 2007, 14, 162-167.	3.3	19
77	Evidence of Pre-Synaptic Dopaminergic Deficit in a Patient with a Novel Progranulin Mutation Presenting with Atypical Parkinsonismâ€. Journal of Alzheimer's Disease, 2013, 38, 747-752.	2.6	19
78	Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients. European Journal of Clinical Pharmacology, 2016, 72, 1335-1341.	1.9	19
79	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. The Lancet Digital Health, 2022, 4, e359-e369.	12.3	19
80	Levodopaâ€induced belly dancer's dyskinesias in Parkinson's disease: Report of one case. Movement Disorders, 2010, 25, 1760-1762.	3.9	18
81	<scp>P</scp> revalence and burden of dysautonomia in advanced Parkinson's disease. Movement Disorders, 2017, 32, 796-797.	3.9	18
82	Chronic obstructive pulmonary disease may complicate Alzheimer's disease: a comorbidity problem. Neurological Sciences, 2018, 39, 1585-1589.	1.9	18
83	E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. Journal of Neuroimmunology, 2005, 165, 201-205.	2.3	17
84	Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2006, 11, 53-60.	3.1	17
85	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes and Immunity, 2010, 11, 497-503.	4.1	17
86	Polymorphisms of Dopamine Receptor Genes and Parkinson's Disease: Clinical Relevance and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 3781.	4.1	17
87	T Lymphocytes in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, S65-S74.	2.8	17
88	Cutaneous silent period in human immunodeficiency virus-related peripheral neuropathy. Journal of the Peripheral Nervous System, 2004, 9, 224-231.	3.1	16
89	Complex movement disorders in primary antiphospholipid syndrome: A case report. Journal of the Neurological Sciences, 2009, 281, 101-103.	0.6	16
90	Rehabilitation improves dyskinesias in Parkinsonian patients: A pilot study comparing two different rehabilitative treatments. NeuroRehabilitation, 2012, 30, 295-301.	1.3	16

#	Article	IF	CITATIONS
91	Spontaneous Intracranial Hypotension Presenting as a Reversible Dorsal Midbrain Syndrome. Journal of Neuro-Ophthalmology, 2008, 28, 289-292.	0.8	15
92	Impaired visual inhibition in migraine with aura. Clinical Neurophysiology, 2015, 126, 1988-1993.	1.5	15
93	Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 507-514.	2.8	15
94	Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Reports, 2011, 2011, bcr1120103549-bcr1120103549.	0.5	14
95	Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients. Brain Sciences, 2021, 11, 1521.	2.3	14
96	Abnormal response to glutamate of T lymphocytes from multiple sclerosis patients. Neuroscience Letters, 2003, 340, 5-8.	2.1	13
97	P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. Neuroscience Letters, 2005, 388, 149-152.	2.1	13
98	MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. Multiple Sclerosis and Related Disorders, 2018, 21, 9-10.	2.0	13
99	Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiologie Clinique, 2020, 50, 47-54.	2.2	13
100	Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103231.	2.0	13
101	The Role of Tau beyond Alzheimer's Disease: A Narrative Review. Biomedicines, 2022, 10, 760.	3.2	12
102	Predicting Cognitive Decline in Parkinsonââ,¬â,,¢s Disease: Can We Ask the Genes?. Frontiers in Neurology, 2014, 5, 224.	2.4	11
103	Longitudinal Assessment of Transorbital Sonography, Visual Acuity, and Biomarkers for Inflammation and Axonal Injury in Optic Neuritis. Disease Markers, 2017, 2017, 1-5.	1.3	11
104	The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson's Disease. Life, 2021, 11, 804.	2.4	10
105	Guillain–BarrÔ syndrome following COVID-19 vaccine mRNA-1273: a case report. Acta Neurologica Belgica, 2022, 122, 1369-1371.	1.1	10
106	Fasâ€mediated Tâ€cell apoptosis in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2011, 16, 45-47.	3.1	9
107	The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function. Human Immunology, 2012, 73, 585-592.	2.4	9
108	Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Genes and Immunity, 2015, 16, 99-102.	4.1	9

#	Article	IF	CITATIONS
109	Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis. Cells, 2019, 8, 262.	4.1	9
110	Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. British Journal of Haematology, 2017, 176, 258-267.	2.5	8
111	Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. Journal of Neuroimaging, 2017, 27, 92-96.	2.0	8
112	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. Journal of Neural Transmission, 2020, 127, 881-891.	2.8	8
113	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 159-167.	2.9	8
114	Change over time of COVID-19 hospital presentation in Northern Italy. European Journal of Internal Medicine, 2020, 81, 100-103.	2.2	7
115	Paraneoplastic neuromyelitis optica spectrum disorders: a case series. Neurological Sciences, 2021, 42, 2519-2522.	1.9	7
116	Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis. Neuroscience Letters, 2007, 425, 173-176.	2.1	6
117	The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study). Journal of Neural Transmission, 2017, 124, 869-879.	2.8	6
118	The vermiform appendix in Parkinson's disease: At the crossroad of peripheral immunity, the nervous system and the intestinal microbiome. Autoimmunity Reviews, 2019, 18, 102357.	5.8	6
119	Editorial: Peripheral Immunity in Parkinson's Disease: Emerging Role and Novel Target for Therapeutics. Frontiers in Neurology, 2019, 10, 1080.	2.4	6
120	Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study. Neural Regeneration Research, 2021, 16, 2475.	3.0	6
121	Striatal dopamine transporter imaging in Parkinson's disease drug-naìve patients: focus on sexual dysfunction. Neurological Sciences, 2022, 43, 4769-4776.	1.9	6
122	Signals of Apoptotic Pathways in Several Types of Meningioma. Pathology and Oncology Research, 2011, 17, 51-59.	1.9	5
123	Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension. Journal of Neurology, 2021, 268, 1006-1015.	3.6	5
124	Increased Prevalence of Neuropsychiatric Disorders during COVID-19 Pandemic in People Needing a Non-Deferrable Neurological Evaluation. Journal of Clinical Medicine, 2021, 10, 5169.	2.4	5
125	Immune Response Modifications in the Genetic Forms of Parkinson's Disease: What Do We Know?. International Journal of Molecular Sciences, 2022, 23, 3476.	4.1	5
126	Expanding the genetic spectrum of primary familial brain calcification due to SLC2OA2 mutations: a case series. Neurogenetics, 2021, 22, 65-70.	1.4	4

#	Article	IF	CITATIONS
127	An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients. Genes, 2021, 12, 1607.	2.4	4
128	MRI imaging and clinical features of sciatic nerve injection injury. International Journal of Neuroscience, 2016, 126, 1-2.	1.6	3
129	Holmes tremor caused by a natalizumab-related progressive multifocal leukoencephalopathy: a case report and brief review of the literature. Neurological Sciences, 2019, 40, 1943-1945.	1.9	3
130	Cortical visuomotor interactions in Freezing of Gait: A TMS approach. Neurophysiologie Clinique, 2020, 50, 205-212.	2.2	3
131	Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population. Frontiers in Genetics, 2021, 12, 800262.	2.3	3
132	The Effects of COVID-19-Related Restrictions on Parkinson's Disease Patients in Italy: Results of a Structured Survey. Journal of Clinical Medicine, 2022, 11, 3007.	2.4	3
133	Post-lumbar puncture headache: an adverse effect in multiple sclerosis work-up. Neurological Sciences, 2019, 40, 759-762.	1.9	2
134	Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood, 2000, 95, 3176-3182.	1.4	2
135	Motor and non-motor symptom improvement after mRNA-1273 vaccine in a Parkinson's disease patient. Neurological Sciences, 2021, , 1.	1.9	2
136	Susac Syndrome: an uncommon cause of impaired vision. Neurological Sciences, 2022, 43, 3919-3922.	1.9	2
137	A patient with autoimmune limb-girdle myasthenia, and a brief review of this treatable condition Clinical Neurology and Neurosurgery, 2017, 158, 53-55.	1.4	1
138	The Immune System as a Therapeutic Target for Old and New Drugs in Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2022, 21, .	1.4	1
139	Early Successful Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Verbal Memory Impairment in an Adjustment Disorder: A Case Report in a Newly-Diagnosed Multiple Sclerosis Patient. Reports, 2022, 5, 17.	0.5	1
140	FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)- $\hat{l}^2$ . Journal of the Neurological Sciences, 2009, 285, S84.	0.6	0
141	Advances in Neuroimmunology: From Bench to Bedside. Autoimmune Diseases, 2014, 2014, 1-2.	0.6	0
142	Polymorphisms of dopamine receptor genes are associated to increased risk of visual hallucinations in Italian Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 22, e170.	2.2	0
143	FRIO258â€ANTI-RO/SSA POSITIVITY, ANTI-AQUAPORIN4 ANTIBODIES AND CENTRAL NERVOUS SYSTEM INVOLVEMENT: A RETROSPECTIVE STUDY ON A CONTROVERSIAL CORRELATION. , 2019, , .		0
144	Neuromyelitis optica with syringomyelia: A case report and neurosonological follow up. Journal of the Neurological Sciences, 2021, 429, 118287.	0.6	0

#	Article	IF	CITATIONS
145	A challenging diagnosis of neurodegenerative dementia: Psychiatric onset of frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2021, 429, 119008.	0.6	0
146	CSF Tau protein correlates with cognitive impairment in multiple sclerosis patients at diagnosis. Journal of the Neurological Sciences, 2021, 429, 117752.	0.6	0
147	The impact of COVID-19 pandemic on cognition of people with dementia. Journal of the Neurological Sciences, 2021, 429, 117797.	0.6	0
148	Why searching for Anti-Contactin-1 antibodies in chronic inflammatory demyelinating polyneuropathy: a case report Neuroimmunology Reports, 2021, 1, 100034.	0.4	0
149	Vogt-Koyanagi-Harada Syndrome: A Case of Bilateral Steroid-Responsive Loss of Vision. , 2019, 1, .		0